Affiliations: Institute of Geriatrics, Tokyo Women's Medical University, Tokyo, Japan | Mitsubishi Kagaku Bio Clinical Laboratories, Tokyo, Japan | Department of Pharmacology, Hamamatsu University, Japan | Hamamatsu Institute of Clinical Pharmacology and Therapeutics, Japan | Japan Immunoresearch Laboratories, Takasaki, Japan
Abstract: Fatty liver disease (FLD) characterised by a high plasma levels of lipoproteins and remnant‐like lipoproteins (RLP) is a risk factor for impaired microvascular blood flow, endothelial cell dysfunction and atherosclerosis. Using an immunoseparation technique with a gel mixture containing human monoclonal antibodies to apo A‐I and apo B‐100, we separated and measured RLP cholesterol (RLP‐C) levels which reflect RLP in patients with FLD (n=20). Whole blood transit time (TT) was determined by a microchannel method (MC‐FAN) which allows blood flow to be viewed via a microscope connected to an image display unit. RLP‐C levels were higher (P<0.01) in FLD, 15.6 ± 1.0 mg/dl compared with 4.8 ± 0.5 mg/dl for controls (n=20). Similarly, TT was longer (P<0.01) in FLD, 284.5 ± 26.1 sec/100 μl compared with 82.8 ± 1.0 sec/100 μl for controls. Since the liver is a major site for RLP formation and degradation, it is affected to a greater extent in patients with FLD. It is likely that high levels of RLP can impair microvascular perfusion in the liver tissue and contribute to the development and progression of FLD.
